Hideko Yamauchi

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

Hideko Yamauchi, A. O’Neill, Rebecca Gelman et al. · Journal of Clinical Oncology · 1997 · 240 citations

Medicine, Oncology, Pharmacology +14

Benefits of off-pump bypass on neurologic and clinical morbidity: a prospective randomized trial

Jeffrey Lee, Shay J. Lee, William T. Tsushima et al. · The Annals of Thoracic Surgery · 2003 · 219 citations

Medicine, Neurology, Surgery +6

Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer

Said Baidas, Eric P. Winer, Gini F. Fleming et al. · Journal of Clinical Oncology · 2000 · 118 citations

Pharmacy, Pharmacokinetics, Pharmacotherapy +17

Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.

Daniel F. Hayes, Hideko Yamauchi, Gloria Broadwater et al. · PubMed · 2001 · 96 citations

Medicine, Cancer Biology, Oncology +17